Home › Trials › NCT06642181
Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 to 55

Guanfacine plus mindfulness to support buprenorphine treatment for opioid use disorder.

Official title: Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder

Run by Rutgers, The State University of New Jersey · NCT06642181 · Data updated 2026-11-12

This trial will test whether adding the medication guanfacine and a mindfulness program to buprenorphine helps adults with opioid use disorder reduce cravings and stay in treatment.

More Opioid Use Disorder trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years to 55 Years
SexAll
Enrollment224 (estimated)
SponsorRutgers, The State University of New Jersey
Academic / other
Locations1 site (Newark, New Jersey)
StatusRecruiting
StartedJuly 15, 2025
Main results expectedAugust 31, 2026
Study endsSeptember 30, 2026
Registry record updatedAugust 8, 2025
Trial IDNCT06642181 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–55 with DSM-5 opioid use disorder who have been maintained on buprenorphine for at least four weeks, have BMI 18–35, a positive urine toxicology for non-prescription opioids, and can read English and provide informed consent are ideal candidates.

Probably not a fit

People with moderate to severe non-opioid substance use disorders (except nicotine), serious psychiatric instability (e.g., current mania or active suicidality), hypotension, pregnancy or nursing, or recent use of medications that affect cerebral function are unlikely to be eligible or to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 interventional study combines the alpha-2 agonist guanfacine with a structured mindfulness program (Mindfulness Oriented Recovery Enhancement, MORE) as adjuncts to ongoing buprenorphine maintenance. Planned enrollment is 224 participants across initial and expansion phases who are adults aged 18–55 and have been stabilized on buprenorphine for at least four weeks. Participants will receive guanfacine pharmacotherapy and group-based MORE sessions at Rutgers in Newark, NJ, with regular clinic visits to monitor craving provoked by stress and opioid cues, urine toxicology, adherence, and safety measures such as blood pressure and EKG. The trial aims to see if the combined medication and behavioral approach reduces relapse risk and improves emotional and reward regulation compared with standard buprenorphine care.

Why it matters

Potential benefit: If successful, this combined pharmacologic and mindfulness approach could reduce stress- and cue-triggered opioid craving and lower relapse rates for people on buprenorphine.

How similar studies have gone: Prior studies indicate guanfacine can reduce stress-provoked craving and mindfulness-based interventions like MORE can reduce cue-provoked craving, but combining both as adjuncts to buprenorphine is a novel approach with limited prior testing.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

N=224 individuals with a history of SCID-5 OUD, and maintained on BUP for at least 4 weeks (N=80 in the R61 phase and N=144 in the R33 phase). These individuals must be:

* aged 18 to 55 years and have a body mass index (BMI) of 18-35;
* have a positive urine toxicology screen for non-prescription opioids
* be in good health as verified by screening examination
* able to read English and provide informed consent.

Exclusion Criteria:

* Current SCID V criteria for a moderate to severe substance use disorder other than opioids or nicotine (although mild use will be permitted)
* Use of medications in the last 6 months that may affect cerebral function with the exception of BUP and individuals stabilized on SSRIs
* psychotic or severely psychiatrically disabled (i.e. suicidal, current mania)
* hypotensive individuals with sitting blood pressure below 100/50 mmHG
* Women who are pregnant, nursing or refuse to use a reliable form of birth control
* EKG evidence at baseline screening of any clinically significant conduction abnormalities (Bazett's QTc of \>450 msec for men and QTc\>470 msec for women)
* R33 phase will additionally include failure to satisfy fMRI safety protocols.

Where it's running

  • Rutgers School of Health Professions
    Newark, New Jersey, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Mindfulness 196Opioid Use Disorder 579Rutgers, The State University of New Jersey 103
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.